Most documented safety issues reported during Enspryng (satralizumab-mwge) treatment for neuromyelitis optica spectrum disorder (NMOSD) in a real-world database have been consistent with the therapy’s reported safety profile in clinical trials, a study showed. Simultaneous use of corticosteroids, a common anti-inflammatory treatment in NMOSD, was associated with higher…
Clinical trials
Infusions of stem cells derived from umbilical cords proved safe for people with neuromyelitis optica spectrum disorder (NMOSD) and look to be a promising new therapy for the autoimmune disease, according to data from an early clinical trial conducted in China. In the trial, the two-year treatment, which consisted…
A U.S.-based registry of adults with neuromyelitis optica spectrum disorder (NMOSD) shows that most patients are receiving biologic therapies, either approved or not approved for NMOSD, in real-world care, according to a study of its first 350 participants. The registry, called SPHERES, has enrolled about half of…
Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…
Infection rates were consistently lower in adults with neuromyelitis optica spectrum disorder (NMSOD) treated with Enspryng (satralizumab-mwge) over other immunosuppressive therapies, according to long-term data from clinical trials and real-world settings. “This analysis provides reassurance that the [Enspryng] safety profile observed in patients with NMOSD in a clinical…
HNSA-5487, Hansa Biopharma’s experimental treatment for neuromyelitis optica spectrum disorder (NMOSD) and other autoimmune diseases, safely and effectively reduced the levels of immunoglobulin G (IgG) antibodies — ones involved in the abnormal immune attacks that drive these conditions — in a Phase 1 clinical trial involving healthy volunteers.
Uplizna (inebilizumab) treatment markedly reduces the number of several subsets of immune B-cells that are linked to disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD), trial data show. The therapy also lowers levels of the self-reactive antibodies against the AQP4 protein that drive most NMOSD cases,…
Nearly all neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) are free of relapses after six months, according to interim data from an ongoing post-marketing surveillance study in Japan. With a relapse rate of only 5% over six months, the findings were “comparable or lower…
Long-term treatment with Uplizna (inebilizumab) was well tolerated and led to sustained disease control for adults with neuromyelitis optica spectrum disorder (NMOSD). That’s according to final data from the open-label extension period of the Phase 2/3 N-MOmentum clinical trial (NCT02200770), top-line data of which supported the therapy’s…
None of the neuromyelitis optica spectrum disorder (NMOSD) patients in the Phase 3 CHAMPION-NMOSD clinical trial have had a disease relapse while on Ultomiris (ravulizumab-cwvz) treatment for a median of more than 2.5 years. These findings were shared by Sean Pittock, MD, the trial’s principal investigator, at the…
Recent Posts
- My mom’s example of strength still guides me in life with NMOSD
- Short course of approved drug effective for treatment-resistant NMOSD
- How to help people in your social circle better understand chronic illness
- New NMOSD study points to silent brain changes between relapses
- Working with a pain management clinic feels like a new world of possibility